Interpretation of the American Joint Committee on Cancer(AJCC)9th Edition Staging System for patients with gastroenteropancreatic neuroendocrine tumors
WU Jia-wen
LI Qi-yuan
SUN Bei
Abstract：Gastroenteropancreatic neuroendocrine tumors(GEP-NETs)exhibit significant heterogeneity and complex prognostic factors,presenting a longstanding challenge in standardizing treatment to improve long-term patient survival.The American Joint Committee on Cancer(AJCC)implemented the 9th edition of the staging system for GEP-NETs in January 2024.Compared to the previous edition,the new system includes several updates:further staging for Nx tumors of the stomach,duodenum/ampulla,appendix,and colon/rectum;emphasize of the importance of endoscopic diagnosis and treatment;emphasis on the diagnosis and treatment of PPI-related gastric neuroendocrine tumors;and updates on certain diagnostic markers and prognostic factors.Overall,the staging system is becoming more precise and comprehensive.The AJCC staging system holds authoritative influence worldwide,and it is anticipated that future evidence-based medical research will further standardize the treatments of GEP-NETs.
Keywords：gastroenteropancreatic neuroendocrine tumorsAJCC stagingtumor heterogeneityendoscopic treatmenttumor markers
Publication Date：2025-01-31
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 48-51,58 )